sitemap
waves
 

News Release

China Pharma News Service initates coverage on Tetrodin(HT)

Date: 2000/01/24

International Wex Technologies Inc. ("IWT") announces that China Concept Consulting of the United Kingdom has completed their due diligence on IWT's Tetrodin(HT) and has begun coverage of Tetrodin(HT) on the China Pharma News website (http://www.chinapharmanews.com).

Tetrodin(HT) has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. IWT has also begun tests on the usage of Tetrodin(HT) as a potent analgesic.

China Pharma News is a new information joint venture between China Concept Consulting and The Information Centre of the State Drug Administration of China ("SDA"). Stories published on this service come from the regional offices of the SDA and many are exclusive to the service.

China Concept Consulting is a leading Beijing based consultancy providing industry information, market strategy and public affairs services to international companies in China and has specific expertise in the Pharmaceuticals sector. For further information, visit their website at http://www.chinaconcept.com or email any questions to Jeremy Gordon, at jgordon@chinaconcept.com .

IWT has developed a patented new product named Tetrodin(HT). Tetrodin(HT) is a non-narcotic pharmaceutical that has proven to be a safe and effective treatment for all opiate (heroin, opium, morphine, methadone, etc.) addictions. Tetrodin(HT) functions very well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

Home | News | Corporate | Products | Investors | Licensing | Contact |

 
Copyright WEX Pharmaceuticals Inc. All rights reserved.
Privacy Policy | Disclaimer
Website designed by Attention Media.